7 results on '"M. Filipits"'
Search Results
2. Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
- Author
-
Wimmer K, Hlauschek D, Balic M, Pfeiler G, Greil R, Singer CF, Halper S, Steger G, Suppan C, Gampenrieder SP, Helfgott R, Egle D, Filipits M, Jakesz R, Sölkner L, Fesl C, Gnant M, and Fitzal F
- Subjects
- Humans, Female, Middle Aged, Prognosis, Aged, Chemotherapy, Adjuvant methods, Neoplasm Recurrence, Local, Adult, Antineoplastic Agents, Hormonal therapeutic use, Clinical Decision-Making, Prospective Studies, Risk Assessment methods, Receptors, Estrogen metabolism, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Breast Neoplasms therapy
- Abstract
Purpose: The Clinical Treatment Score post-5 years (CTS5) is an easy-to-use tool estimating the late distant recurrence (LDR) risk in patients with hormone receptor-positive breast cancer after 5 years of endocrine therapy (ET). Apart from evaluating the prognostic value and calibration accuracy of CTS5, the aim of this study is to clarify if this score is able to identify patients at higher risk for LDR who will benefit from extended ET., Methods: Prognostic power, calibration, and predictive value of the CTS5 was tested in patients of the prospective ABCSG-06 and -06a trials (n = 1254 and 860 patients, respectively). Time to LDR was analyzed with Cox regression models., Results: Higher rates of LDR in the years five to ten were observed in high- and intermediate-risk patients compared to low-risk patients (HR 4.02, 95%CI 2.26-7.15, p < 0.001 and HR 1.93, 95%CI 1.05-3.56, p = 0.035). An increasing continuous CTS5 was associated with increasing LDR risk (HR 2.23, 95% CI 1.74-2.85, p < 0.001). Miscalibration of CTS5 in high-risk patients could be observed. Although not reaching significance, high-risk patients benefitted the most from prolonged ET with an absolute reduction of the estimated 5-year LDR of - 6.1% (95%CI - 14.4 to 2.3)., Conclusion: The CTS5 is a reliable prognostic tool that is well calibrated in the lower and intermediate risk groups with a substantial difference of expected versus observed LDR rates in high-risk patients. While a numerical trend in favoring prolonged ET for patients with a higher CTS5 was found, a significantly predictive value for the score could not be confirmed., Clinical Trial Registration: ABCSG-06 trial (NCT00309491), ABCSG-06A7 1033AU/0001 (NCT00300508)., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
3. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
- Author
-
Sestak I, Martín M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, Filipits M, Ruiz A, Gradishar W, Soliman H, Schwartzberg L, Buus R, Hlauschek D, Rodríguez-Lescure A, and Gnant M
- Subjects
- Aged, Breast Neoplasms metabolism, Chemotherapy, Adjuvant, Clinical Trials as Topic, Combined Modality Therapy, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Female, Fluorouracil therapeutic use, Humans, Kaplan-Meier Estimate, Middle Aged, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Retrospective Studies, Risk Assessment, Treatment Outcome, Antineoplastic Agents, Hormonal therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy
- Abstract
Purpose: EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we determine the performance of EPclin for estimating 10-year distant recurrence-free interval (DRFI) rates for those who received adjuvant endocrine therapy (ET) alone compared to those with chemotherapy plus endocrine therapy (ET + C)., Methods: A total of 3746 women were included in this joint analysis. 2630 patients received 5 years of ET alone (ABCSG-6/8, TransATAC) and 1116 patients received ET + C (GEICAM 2003-02/9906). The primary objective was to evaluate the ability of EPclin to provide an estimate of the 10-year DR rate as a continuous function of EPclin separately for ET alone and ET + C. Cox proportional hazard models were used for these analyses., Results: EPclin was highly prognostic for DR in women who received ET alone (HR 2.79 (2.49-3.13), P < 0.0001) as well as in those who received ET + C (HR 2.27 (1.99-2.59), P < 0.0001). Women who received ET + C had significantly smaller increases in 10-year DR rates with the increasing EPclin score than those receiving ET alone (EPclin = 5; 12% ET + C vs. 20% ET alone). We observed a significant positive interaction between EPclin and treatment groups (P-
interaction = 0.022)., Conclusions: In this comparative non-randomised analysis, the rate of increase in DR with EPclin score was significantly reduced in women who received ET + C versus ET alone. Our indirect comparisons suggest that a high EPclin score can predict chemotherapy benefit in women with ER-positive, HER2-negative disease.- Published
- 2019
- Full Text
- View/download PDF
4. Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer.
- Author
-
Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, Markis-Ritzinger EM, Kandioler D, Berger W, Stiglbauer W, Depisch D, Pirker R, Zielinski CC, and Zöchbauer-Müller S
- Subjects
- Azacitidine analogs & derivatives, Azacitidine chemistry, Carcinoma metabolism, Cell Adhesion, Cell Adhesion Molecule-1, Cell Adhesion Molecules, Cell Line, Tumor, DNA Methylation, Decitabine, Epigenesis, Genetic, Female, Humans, Microfilament Proteins, RNA metabolism, Reverse Transcriptase Polymerase Chain Reaction, Sulfites chemistry, Breast Neoplasms genetics, Breast Neoplasms metabolism, Gene Expression Regulation, Neoplastic, Immunoglobulins biosynthesis, Immunoglobulins genetics, Membrane Proteins biosynthesis, Membrane Proteins genetics, Tumor Suppressor Proteins biosynthesis, Tumor Suppressor Proteins genetics
- Abstract
TSLC1 and DAL-1 are tumor suppressor genes involved in cell adhesion. In this study, we examined the expression and methylation pattern of these genes in breast cancer cell lines and primary breast carcinomas. TSLC1 expression was lost in 5 of 8 (63%) and DAL-1 expression was lost in 6 of 8 (75%) breast cancer cell lines, respectively. Downregulation of TSLC1 expression was observed in 43 of 50 (86%) and of DAL-1 expression in 26 of 55 (47%) primary breast carcinomas. TSLC1 methylation was found in 4 of 8 (50%) and DAL-1 methylation was observed in 6 of 8 (75%) breast cancer cell lines, respectively. Of 95 primary breast carcinomas 46 (48%) were TSLC1 methylated and 26 (27%) were DAL-1 methylated. Twenty of 43 (47%) and 10 of 26 (38%) primary breast cancer samples which showed downregulation of TSLC1 and DAL-1 expression were unmethylated for these genes. Re-expression of TSLC1 and DAL-1 was observed after treatment of BT-20 cells with 5-aza-2'-deoxycytidine and TSA. Samples from patients with grade 3 tumors were more frequently TSLC1 and TSLC1 and/or DAL-1 methylated than samples from patients with grade 1 and 2 tumors (P = 0.032, P = 0.023). Moreover, TSLC1 methylation correlated with loss of both ER and PgR staining (P = 0.011, P = 0.02). Our findings suggest that TSLC1 and DAL-1 are involved in the pathogenesis of breast cancer and are frequently inactivated by methylation.
- Published
- 2007
- Full Text
- View/download PDF
5. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy.
- Author
-
Rudas M, Filipits M, Taucher S, Stranzl T, Steger GG, Jakesz R, Pirker R, and Pohl G
- Subjects
- Adult, Aged, Breast Neoplasms drug therapy, Carcinoma, Ductal, Breast drug therapy, Chemotherapy, Adjuvant, Drug Resistance, Multiple drug effects, Drug Resistance, Neoplasm drug effects, Female, Humans, Immunohistochemistry, Middle Aged, Neoadjuvant Therapy, Proportional Hazards Models, Survival Analysis, ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms metabolism, Carcinoma, Ductal, Breast metabolism, Multidrug Resistance-Associated Proteins metabolism, Neoplasm Proteins metabolism, Vault Ribonucleoprotein Particles metabolism
- Abstract
Our purpose was to determine the expression of the drug resistance factors multidrug resistance protein (MRP1), lung resistance protein (LRP) and P-glycoprotein (Pgp) in breast carcinoma patients treated with preoperative chemotherapy. We have studied the expression of these proteins in breast carcinomas by immunohistochemistry both prior (n = 80) and after (n = 68) preoperative chemotherapy and compared their expression with response to preoperative chemotherapy. In paired samples prior and after chemotherapy expression of drug resistance factors was significantly lower in prechemotherapy samples as compared with postchemotherapy specimens. This was observed for MRP1 (62% vs. 88%, P < 0.001), LRP (65% vs. 97%, P < 0.001) and Pgp (55% vs. 100%, P < 0.001). Prechemotherapy expression of MRP1 was more frequently observed in patients with distant metastases than in those without (50% vs. 8%, P = 0.02). No associations were observed between LRP expression and clinical parameters. Pgp expression was more frequently detected in lobular carcinomas than in ductal carcinomas (93% vs. 46%, P = 0.001) and in patients with positive lymph nodes than in patients with negative lymph nodes (65% vs. 31%, P = 0.008) but was independent of other clinical parameters. No significant associations were found between the prechemotherapy or postchemotherapy expression of either of these three proteins and response to preoperative chemotherapy. However, prechemotherapy MRP1 expression was significantly associated with shorter progression-free survival of the patients (P = 0.02), whereas no such associations were observed for either LRP or Pgp. In conclusion, preoperative chemotherapy increases the expression of MRP1, LRP and Pgp. Response to chemotherapy is not associated with pre- or postchemotherapy expression levels of these drug resistance proteins but time to progression may be influenced by prechemotherapy MRP1 expression.
- Published
- 2003
- Full Text
- View/download PDF
6. Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy.
- Author
-
Pohl G, Rudas M, Taucher S, Stranzl T, Steger GG, Jakesz R, Pirker R, and Filipits M
- Subjects
- Adult, Aged, Breast Neoplasms metabolism, Cell Cycle Proteins drug effects, Cell Cycle Proteins genetics, Chemotherapy, Adjuvant methods, Cyclin D3, Cyclin-Dependent Kinase Inhibitor p21, Cyclin-Dependent Kinase Inhibitor p27, Cyclins drug effects, Cyclins genetics, Cyclophosphamide administration & dosage, Docetaxel, Enzyme Inhibitors pharmacology, Epirubicin administration & dosage, Female, Fluorouracil administration & dosage, Genes, Tumor Suppressor drug effects, Genes, p53 drug effects, Genes, p53 genetics, Humans, Ki-67 Antigen drug effects, Ki-67 Antigen genetics, Methotrexate administration & dosage, Middle Aged, Paclitaxel administration & dosage, Preoperative Care, Receptors, Steroid drug effects, Treatment Outcome, Tumor Suppressor Proteins drug effects, Tumor Suppressor Proteins genetics, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Breast Neoplasms genetics, Breast Neoplasms therapy, Gene Expression genetics, Paclitaxel analogs & derivatives, Taxoids, Transcription Factors genetics
- Abstract
Molecular markers predicting response to preoperative chemotherapy would be of major clinical relevance in breast cancer. Therefore, we studied the relationship between the expression of cell cycle regulatory proteins and clinical outcome in breast cancer patients receiving preoperative chemotherapy. Expression of p2lWaf1, p27KiP1, p53, cyclin D3 and Ki-67 was determined in breast carcinomas by means of immunohistochemistry both prior and after preoperative chemotherapy. Expression data were compared with both clinical parameters and response to preoperative chemotherapy with either cyclophosphamide/methotrexate/5-fluorouracil (CMF, n = 29) or epirubicin/docetaxel (ED, n = 36). In paired samples before and after preoperative chemotherapy, the percentage of p21Waf1, p27Kip1, p53 and cyclin D3 positive nuclei of tumor cells in postchemotherapy specimens was significantly higher than the percentage in prechemotherapy samples but no change in Ki-67 expression was observed. High Ki-67 expression (p = 0.02), negative estrogen receptor status (p = 0.01) and negative progesterone receptor status (p = 0.04) were associated with complete pathologic response to chemotherapy, whereas the other markers did not predict response. In conclusion, expression levels of p21Waf1, p27Kip1, p53 and cyclin D3 significantly increased after preoperative chemotherapy in breast carcinomas but only high Ki-67 expression, negative estrogen receptor status and negative progesterone receptor status were associated with complete pathologic response to preoperative chemotherapy.
- Published
- 2003
- Full Text
- View/download PDF
7. Aneuploidy of chromosome 8 as detected by interphase fluorescence in situ hybridization is a recurrent finding in primary and metastatic breast cancer.
- Author
-
Roka S, Fiegl M, Zojer N, Filipits M, Schuster R, Steiner B, Jakesz R, Huber H, and Drach J
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms ultrastructure, Carcinoma, Ductal, Breast ultrastructure, Female, Humans, In Situ Hybridization, Fluorescence, Interphase, Middle Aged, Neoplasm Metastasis, Aneuploidy, Breast Neoplasms pathology, Carcinoma, Ductal, Breast pathology, Chromosomes, Human, Pair 8
- Abstract
Previous work from our laboratory demonstrated aneuploidy for several chromosomes by interphase fluorescence in situ hybridization (FISH) in a high proportion of breast cancer specimens. In the literature, only limited data are available concerning chromosome 8 anomalies in breast cancer. To determine chromosome 8 ploidy status in primary and metastatic specimens from 81 breast cancer patients, FISH analysis with a DNA probe recognizing chromosome 8 centromeres was performed. In all primary tumor specimens (n = 30), significant proportions of cells were aneuploid exhibiting gain of chromosome 8 copy numbers; in 75% of effusion specimens previously classified as malignant by cytology and/or FISH for various chromosomes (n = 40), cell populations aneuploid for chromosome 8 were detected; effusions previously classified non-malignant (n = 11) were diploid in 10 cases, whereas one specimen contained rare hyperdiploid cells. Among these cells complex chromosomal aneuploidy could be demonstrated by two-color FISH, suggesting malignancy. Trisomic and tetrasomic clones were predominant in the majority of samples, but a marked intratumor cytogenetic heterogeneity was observed in most cases. Primary tumors and corresponding positive axillary lymph nodes revealed similar distributions of chromosome 8 copy numbers, analogous to previous findings with other chromosomes. This implies that, by using suitable FISH probes after examination of the respective primary tumor, an efficient search for (micro)metastasis might be feasible.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.